Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

411
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
411
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

340
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
340
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

859
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
859
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

597
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
597
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

637
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
637
Pneumonia IV: Management01:28

Pneumonia IV: Management

639
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
639

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global burden of metabolic dysfunction-associated steatotic liver disease attributable to tobacco, 1990-2023, and projected trends to 2038.

Journal of diabetes and metabolic disorders·2026
Same author

Relationship between dietary selenium intake and hyperlipidemia: a population-based study from NHANES (2011-2018).

Irish journal of medical science·2026
Same author

Enhancing synergistic removal of gaseous mercury by low-valence sulfur engineered V<sub>2</sub>O<sub>5</sub>-WS<sub>2</sub>/TiO<sub>2</sub> SCR catalysts.

Journal of environmental management·2026
Same author

The Power of Faith.

JAMA internal medicine·2025
Same author

Are Procalcitonin Measures a Reliable Predictor of Stopping Antibiotics Among Patients With Sepsis?

JAMA·2025
Same author

Predictive Significance of Admission-Day Blood Routine-Derived Indices for 30-Day Mortality Risk in Elderly Patients with Bacterial Pneumonia.

International journal of general medicine·2025

Related Experiment Video

Updated: Dec 13, 2025

Rescue of Recombinant Newcastle Disease Virus from cDNA
10:55

Rescue of Recombinant Newcastle Disease Virus from cDNA

Published on: October 11, 2013

19.9K

Intravenous Interferon β-1a for Severe ARDS

Xianshi Zhou1, Guanghua Tang1

  • 1Emergency Department, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.

JAMA
|August 5, 2020
PubMed
Summary

No abstract available in PubMed .

More Related Videos

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

8.2K
Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

16.8K

Related Experiment Videos

Last Updated: Dec 13, 2025

Rescue of Recombinant Newcastle Disease Virus from cDNA
10:55

Rescue of Recombinant Newcastle Disease Virus from cDNA

Published on: October 11, 2013

19.9K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

8.2K
Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

16.8K